|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DTD1 |
Gene summary for DTD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DTD1 | Gene ID | 92675 |
| Gene name | D-aminoacyl-tRNA deacylase 1 | |
| Gene Alias | C20orf88 | |
| Cytomap | 20p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8TEA8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92675 | DTD1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.60e-02 | 2.42e-01 | -0.1808 |
| 92675 | DTD1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.34e-07 | 3.86e-01 | -0.0811 |
| 92675 | DTD1 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.37e-08 | 2.89e-01 | -0.1088 |
| 92675 | DTD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.57e-05 | 1.93e-01 | -0.1954 |
| 92675 | DTD1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.66e-06 | 3.19e-01 | -0.1526 |
| 92675 | DTD1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.85e-05 | 2.01e-01 | -0.1464 |
| 92675 | DTD1 | HTA11_866_2000001011 | Human | Colorectum | AD | 8.86e-03 | 1.73e-01 | -0.1001 |
| 92675 | DTD1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.76e-13 | 3.72e-01 | -0.059 |
| 92675 | DTD1 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.69e-12 | 3.70e-01 | 0.096 |
| 92675 | DTD1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.01e-03 | 4.25e-01 | 0.0446 |
| 92675 | DTD1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.05e-03 | 3.68e-01 | 0.0528 |
| 92675 | DTD1 | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.98e-02 | 2.66e-01 | -0.0177 |
| 92675 | DTD1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.08e-03 | 2.42e-01 | 0.0338 |
| 92675 | DTD1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.57e-15 | 3.54e-01 | 0.0674 |
| 92675 | DTD1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.66e-02 | 2.38e-01 | 0.0588 |
| 92675 | DTD1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.24e-22 | 4.66e-01 | 0.294 |
| 92675 | DTD1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.59e-06 | 8.72e-01 | 0.3487 |
| 92675 | DTD1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.44e-05 | 2.83e-01 | 0.281 |
| 92675 | DTD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.70e-03 | 1.80e-01 | 0.3859 |
| 92675 | DTD1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.12e-21 | 4.34e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034660 | Colorectum | MSI-H | ncRNA metabolic process | 53/1319 | 485/18723 | 9.66e-04 | 1.68e-02 | 53 |
| GO:0006260 | Colorectum | MSI-H | DNA replication | 31/1319 | 260/18723 | 2.83e-03 | 3.63e-02 | 31 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
| GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
| GO:003466013 | Skin | cSCC | ncRNA metabolic process | 234/4864 | 485/18723 | 1.37e-26 | 4.77e-24 | 234 |
| GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
| GO:00063993 | Skin | cSCC | tRNA metabolic process | 64/4864 | 179/18723 | 2.34e-03 | 1.36e-02 | 64 |
| GO:00346608 | Thyroid | PTC | ncRNA metabolic process | 239/5968 | 485/18723 | 5.54e-16 | 4.26e-14 | 239 |
| GO:00062606 | Thyroid | PTC | DNA replication | 114/5968 | 260/18723 | 3.09e-05 | 2.95e-04 | 114 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DTD1 | SNV | Missense_Mutation | c.275N>G | p.Asp92Gly | p.D92G | Q8TEA8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| DTD1 | SNV | Missense_Mutation | novel | c.566N>A | p.Arg189Gln | p.R189Q | Q8TEA8 | protein_coding | deleterious_low_confidence(0.02) | benign(0.152) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DTD1 | insertion | In_Frame_Ins | novel | c.337_338insAGACCTCAACGCTAAGTCAGCCTT | p.Gln112_Leu113insGlnThrSerThrLeuSerGlnPro | p.Q112_L113insQTSTLSQP | Q8TEA8 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| DTD1 | SNV | Missense_Mutation | rs146358079 | c.578N>A | p.Arg193His | p.R193H | Q8TEA8 | protein_coding | tolerated_low_confidence(0.21) | benign(0.057) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DTD1 | SNV | Missense_Mutation | novel | c.307N>A | p.Glu103Lys | p.E103K | Q8TEA8 | protein_coding | tolerated(1) | benign(0.006) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| DTD1 | SNV | Missense_Mutation | rs761352624 | c.158N>A | p.Arg53His | p.R53H | Q8TEA8 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DTD1 | SNV | Missense_Mutation | rs754144369 | c.583N>A | p.Ala195Thr | p.A195T | Q8TEA8 | protein_coding | tolerated_low_confidence(0.06) | benign(0.006) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| DTD1 | SNV | Missense_Mutation | c.85N>C | p.Val29Leu | p.V29L | Q8TEA8 | protein_coding | deleterious(0) | possibly_damaging(0.465) | TCGA-F4-6461-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| DTD1 | SNV | Missense_Mutation | novel | c.167A>T | p.Glu56Val | p.E56V | Q8TEA8 | protein_coding | deleterious(0.02) | benign(0.011) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| DTD1 | SNV | Missense_Mutation | rs753802514 | c.356C>T | p.Pro119Leu | p.P119L | Q8TEA8 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AG-A02G-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |